Mapping CNS Changes to Frovatriptan Administration in Acute Treatment of Prodrome or Preventative Treatment of Menstrual Migraine (MM).

Trial Profile

Mapping CNS Changes to Frovatriptan Administration in Acute Treatment of Prodrome or Preventative Treatment of Menstrual Migraine (MM).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 May 2010

At a glance

  • Drugs Frovatriptan (Primary)
  • Indications Menstrual migraine
  • Focus Pharmacodynamics
  • Most Recent Events

    • 26 May 2010 Planned end date (May 2010) added as reported by ClinicalTrials.gov.
    • 26 May 2010 Actual initiation date (Apr 2010) added as reported by ClinicalTrials.gov.
    • 26 May 2010 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top